Safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus from Gulf countries during Ramadan holy month: A subgroup analysis of the SoliRam observational study

•This subanalysis of the SoliRam study was conducted in people with type 2 diabetes mellitus receiving iGlarLixi during Ramadan in Gulf countries.•iGlarLixi was associated with low risk of hypoglycemia, including during Ramadan fasting.•Improvements were observed in HbA1c, FPG and body weight from pre-Ramadan to post-Ramadan.•The benefits of iGlarLixi were seen both during and post-Ramadan. To investigate safety and effectiveness of iGlarLixi in adults with type 2 diabetes mellitus (T2DM) observing fast during Ramadan from Gulf countries. This planned subgroup analysis of the SoliRam – a multinational, prospective, non-interventional, real-world, observational study – focused on participants from Gulf countries. Primary endpoint was proportion of participants experiencing ≥1 episode of severe and/or symptomatic documented (